SMAD3 and cutaneous melanoma: Next, we examined the SMAD3 signature in a large panel of melanoma cell lines representative of the distinct differentiation states (U ‐ NC ‐T ‐ M) (n = 53) (Fig 7D) and cutaneous melanoma (n = 118, TCGA cohort, tumors not exposed to targeted therapy; Fig 7E).